USFDA issues EIR for OmniChem facility
Shares of pharma firm Granules India Ltd. on Friday gained 6.37% to close at ₹121.85 on the back of the U.S. Food and Drug Administration issuing the Establishment Inspection Report (EIR) for the OmniChem facility in Visakhapatnam. The facility, which manufactures API intermediates, is a 50:50 joint venture of Granules India and Ajinomoto OmniChem N.V. The USFDA has issued EIR for the facility, Granules said in a regulatory filing to the stock exchange.
The regulator had inspected the facility in December 2016 and made seven observations, the release said.
ADVERTISEMENT
This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every
month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
You have read {{data.cm.views}} out of {{data.cm.maxViews}} free articles.
This is your last free article.